Product category:
Contract research
News Release from: LGC
Edited by the Laboratorytalk Editorial
Team on 25 March 2004
Teamwork to boost drug development
services
LGC links with Akos, a specialist drug development and regulatory affairs consultancy company, to enable both to expand the range of services they offer to drug discovery companies
LGC has formed a strategic alliance with Akos, a UK-based specialist drug development and regulatory affairs consultancy company, that will enable both parties to expand the range of services they offer to drug discovery companies Akos specialises in leading clients from drug discovery through the development process, and has a strong track record of enabling organisations to achieve their strategic aims, including onward sale or licensing, through to marketing authorisation
This article was originally published on Laboratorytalk on 10 Jun 2002 at 8.00am (UK)
Related stories
New FTMS for LGC
LGC selects £500k Bruker Daltonics Fourier transform instrument to expand its mass spectrometry capability for chemical and bio-molecules
Catalogue of abuse
Reference materials for clinical, forensic and toxicological analysis updated to include new matrix materials including drugs of abuse in saliva
LGC offers a wide range of analytical services and instrumentation that are applied across the drug development cycle from early phase discovery through to clinical trial.
Through this alliance clients will benefit from the best in advice and services that will enhance the development and valuation of new products.
Derek Craston, head of LGC's pharmaceutical services, said: "We are very excited about this collaboration and see Akos as a natural and synergistic partner in providing high value services to the pharmaceutical and biotechnology sectors.
"LGC has strong links with government and regulators, and is committed to supplying high quality analytical services in support of drug discovery.
"We are impressed with Akos and the nearly 20 years of experience that this company has in advising on all types of regulatory compliance issues and providing other services relating to clinical trials and marketing authorisation applications, in Europe, North America and other parts of the world.
"Together, LGC and Akos will be able provide top class support to companies from the earliest phases of lead identification through to market launch".
Paul Evans, chairman and managing director of Akos, commented: "Akos is both a service company and a consultancy: we tailor our response to the clinical, financial or administration needs of the client, working with them from the preclinical phase of drug discovery through early clinical development to 'proof of concept'.
"LGC has a world class reputation for quality and offers a broad range of analytical services, from synthesis and biomeasurement to formulation development.
"We look forward to working with LGC and we believe that together, Akos and LGC can develop a win-win relationship.".
• LGC: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
